TY  - JOUR
AU  - De la Torre Hernández, José M
AU  - Sadaba Sagredo, Mario
AU  - Telleria Arrieta, Miren
AU  - Gimeno de Carlos, Federico
AU  - Sanchez Lacuesta, Elena
AU  - Bullones Ramírez, Juan A
AU  - Pineda Rocamora, Javier
AU  - Martin Yuste, Victoria
AU  - Garcia Camarero, Tamara
AU  - Larman, Mariano
AU  - Rumoroso, Jose R
PY  - 2017
DO  - 10.1186/s12872-017-0636-9
UR  - https://hdl.handle.net/10668/25452
T2  - BMC cardiovascular disorders
AB  - Thrombolysis is still used when primary angioplasty is delayed for a long time, but 25%-30% of patients require rescue angioplasty (RA). There are no established recommendations for antithrombotic management in RA. This registry analyzes regimens for...
LA  - en
KW  - Acute myocardial infarction
KW  - Angioplasty
KW  - Anticoagulation
KW  - Thrombolytic therapy
KW  - Abciximab
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - Chi-Square Distribution
KW  - Coronary Thrombosis
KW  - Drug Administration Schedule
KW  - Enoxaparin
KW  - Female
KW  - Fibrinolytic Agents
KW  - Hemorrhage
KW  - Hirudins
KW  - Humans
KW  - Immunoglobulin Fab Fragments
KW  - Logistic Models
KW  - Male
KW  - Middle Aged
KW  - Multivariate Analysis
KW  - Myocardial Infarction
KW  - Odds Ratio
KW  - Peptide Fragments
KW  - Percutaneous Coronary Intervention
KW  - Recombinant Proteins
KW  - Registries
KW  - Retrospective Studies
KW  - Risk Factors
KW  - Spain
KW  - Thrombolytic Therapy
KW  - Time Factors
KW  - Treatment Failure
TI  - Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry.
TY  - research article
VL  - 17
ER  -